Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis

BACKGROUND: Severe asthma is a heterogeneous inflammatory disease driven by eosinophilic inflammation in the majority of cases. Despite biologic therapy patients may still be sub-optimally controlled, and the choice of the best biologic is a matter of debate. Indeed, switching between biologics is c...

Descripción completa

Detalles Bibliográficos
Autores principales: Caruso, Cristiano, Cameli, Paolo, Altieri, Elena, Aliani, Maria, Bracciale, Pietro, Brussino, Luisa, Caiaffa, Maria Filomena, Canonica, Giorgio Walter, Centanni, Stefano, D’Amato, Maria, Del Giacco, Stefano, De Michele, Fausto, Pastorello, Elide Anna, Pelaia, Girolamo, Rogliani, Paola, Romagnoli, Micaela, Schino, Pietro, Caminati, Marco, Vultaggio, Alessandra, Zullo, Alessandro, Rizzoli, Sara, Boarino, Silvia, Vitiello, Gianfranco, Menzella, Francesco, Di Marco, Fabiano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478391/
https://www.ncbi.nlm.nih.gov/pubmed/36117962
http://dx.doi.org/10.3389/fmed.2022.950883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478391/
https://www.ncbi.nlm.nih.gov/pubmed/36117962
http://dx.doi.org/10.3389/fmed.2022.950883

Ejemplares similares